SE457143B - Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin - Google Patents

Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin

Info

Publication number
SE457143B
SE457143B SE8400851A SE8400851A SE457143B SE 457143 B SE457143 B SE 457143B SE 8400851 A SE8400851 A SE 8400851A SE 8400851 A SE8400851 A SE 8400851A SE 457143 B SE457143 B SE 457143B
Authority
SE
Sweden
Prior art keywords
coenzyme
carnitine
pharmaceutical composition
carnitin
acetyl
Prior art date
Application number
SE8400851A
Other languages
English (en)
Swedish (sv)
Other versions
SE8400851L (sv
SE8400851D0 (sv
Inventor
A Bertelli
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SE8400851D0 publication Critical patent/SE8400851D0/xx
Publication of SE8400851L publication Critical patent/SE8400851L/xx
Publication of SE457143B publication Critical patent/SE457143B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE8400851A 1983-02-16 1984-02-16 Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin SE457143B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Publications (3)

Publication Number Publication Date
SE8400851D0 SE8400851D0 (sv) 1984-02-16
SE8400851L SE8400851L (sv) 1984-08-17
SE457143B true SE457143B (sv) 1988-12-05

Family

ID=4196830

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8400851A SE457143B (sv) 1983-02-16 1984-02-16 Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin

Country Status (11)

Country Link
US (1) US4599232A (nl)
JP (1) JPS59186914A (nl)
BE (1) BE898918A (nl)
CH (1) CH655005A5 (nl)
DE (1) DE3405581A1 (nl)
DK (1) DK165167C (nl)
FR (1) FR2543827B1 (nl)
GB (1) GB2137088B (nl)
IT (1) IT1170235B (nl)
NL (1) NL192778C (nl)
SE (1) SE457143B (nl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
CH670763A5 (nl) * 1985-08-02 1989-07-14 Seuref Ag
CH666183A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
SE8703321D0 (sv) * 1987-08-27 1987-08-27 Sockerbolaget Ab Kostforsterkning
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
GB8907276D0 (en) * 1989-03-31 1989-05-17 Therapy Advisory Services Limi Health supplement
AT393954B (de) * 1990-02-28 1992-01-10 Bock Orthopaed Ind Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
ATE271614T1 (de) * 1992-05-28 2004-08-15 Ct For Molecular Biology And M Quinone-derivate zur verbesserung der zellulare bioenergie
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
ES2201467T3 (es) * 1997-03-27 2004-03-16 Michael J. Sole Composicion nutritiva para la mejora energetica de la celula.
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina
WO2001032168A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
WO2001058271A1 (en) * 2000-01-25 2001-08-16 Juvenon, Inc. Nutritional supplements for aged pets
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
AU2002309038B2 (en) * 2001-05-10 2007-05-17 Kaneka Corporation Compositions for transmucosal administration containing coenzyme Q as the active ingredient
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
EP1643863A2 (en) * 2003-07-10 2006-04-12 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
CN101022793B (zh) * 2004-06-29 2011-05-11 美国益力斯林公司 用以促进新陈代谢和降低活性氧水平的食品组合物
CA2610152C (en) * 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20050249803A1 (en) * 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
SI1933821T1 (sl) * 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
US20100022629A1 (en) * 2006-01-13 2010-01-28 Elixirin Dietary Methods and Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US7615324B2 (en) * 2007-03-14 2009-11-10 Fujifilm Corporation Photosensitive composition, and cured relief pattern production method and semiconductor device using the same
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ES2306610B1 (es) * 2007-04-16 2009-09-11 Universidad De Sevilla Uso de la l-carnitina para el tratamiento de la hipertension arterial.
TW200916090A (en) * 2007-06-22 2009-04-16 Kaneka Corp Composition comprising coenzyme Q10
TW200918096A (en) * 2007-06-22 2009-05-01 Kaneka Corp Composition comprising bioactive substance
WO2009025277A1 (ja) * 2007-08-22 2009-02-26 Kaneka Corporation 還元型補酵素ｑ10の製造方法、ならびに、その安定化方法
TWI478709B (zh) * 2008-02-19 2015-04-01 Earnest Medicine Co Ltd A useful oral or enteral composition for the recovery of bodily functions
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene

Also Published As

Publication number Publication date
IT1170235B (it) 1987-06-03
NL192778B (nl) 1997-10-01
FR2543827A1 (fr) 1984-10-12
JPH027572B2 (nl) 1990-02-19
US4599232A (en) 1986-07-08
DK165167B (da) 1992-10-19
IT8323559A0 (it) 1983-10-31
DK165167C (da) 1993-03-01
SE8400851L (sv) 1984-08-17
GB8403668D0 (en) 1984-03-14
GB2137088B (en) 1986-02-05
DK72284D0 (da) 1984-02-16
JPS59186914A (ja) 1984-10-23
GB2137088A (en) 1984-10-03
SE8400851D0 (sv) 1984-02-16
NL8400488A (nl) 1984-09-17
DE3405581A1 (de) 1984-10-18
DE3405581C2 (nl) 1992-10-22
NL192778C (nl) 1998-02-03
BE898918A (nl) 1984-08-16
FR2543827B1 (fr) 1987-06-12
DK72284A (da) 1984-08-17
CH655005A5 (it) 1986-03-27

Similar Documents

Publication Publication Date Title
SE457143B (sv) Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin
DE69910559T2 (de) Neue fettanaloge zur behandlung der fettleibigkeit
Danilenko et al. Metabolic cardioprotection: new conceptsin implementation of cardioprotective effects of meldonium
US6733793B2 (en) Oral composition with insulin-like activities and methods of use
CZ20023935A3 (cs) Preparáty biochemických sloučenin majících roli v bioenergetickém metabolismu buněk a způsob jejich použití
EP0167115B1 (en) New derivatives of l-carnitine
CN112203650A (zh) 使用烟酰胺腺嘌呤二核苷酸(nad+)前体和至少一种酮或酮前体的组合物和方法
NL8200022A (nl) Farmaceutische samenstelling, die gamma-butyrobetaine bevat, voor de behandeling van door l-carnitine gebrek teweeggebrachte syndromen.
KR20070108383A (ko) 지질 저하성 화합물
US20220288018A1 (en) Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
US4315944A (en) Pharmaceutical composition comprising L-carnitine for the treatment of hyperlipidaemias and hyperlipoproteinaemias
JPS62190190A (ja) Ｌ−カルニチンのホスホリルアルカノ−ルアミド誘導体類およびその医薬組成物
CN101652134A (zh) 用于预防和/或治疗脂肪肝或非酒精性脂肪性肝炎的药物
RU2636616C1 (ru) Комбинированное лекарственное средство для первичной нейропротекции
Gildea The Ketogenic Diet: A Summary.
ES2267796T3 (es) Uso de fibratos para la preparacion de un medicamento util en el tratamiento de insuficiencia cardiaca congestiva.
US20220323479A1 (en) Compositions and methods using adenosylcobalamin
Bessman et al. Ammonia inhibits insulin stimulation of the Krebs cycle: further insight into mechanism of hepatic coma
US7919533B2 (en) Diiodothyroacetic acid and method of use
CA2924682C (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
Albert et al. Differences in distribution: the first principle of selectivity
Sahyun Melville Sahyun: a scientific retrospective
JPS61501561A (ja) 脊椎動物における低血糖症を治療する方法
WO2007075151A1 (en) Composite vasodilator based on a no-group donator and a promoter
Constantine DIETARY CHOLESTEROL ON FREE AND BOUND CHOLESTEROL AND LIPID-PHOSPHORUS CONTENT OF RABBIT AND RAT AORTA, HEART MUSCLE, PLASMA AND ADRENAL.

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8400851-5

Format of ref document f/p: F

NUG Patent has lapsed